Muscle-Invasive Bladder Cancer (MIBC): Treatment

Muscle-Invasive Bladder Cancer (MIBC): overview

This algorithm addresses curative-intent treatment of muscle-invasive bladder cancer (cT2 to 4a N0 M0), with cisplatin eligibility as the main branch point and separate paths for adjuvant therapy and bladder preservation.

For cisplatin-eligible patients, the standard approach is neoadjuvant cisplatin-based chemotherapy (ddMVAC or GC) followed by cystectomy. A newer perioperative option adds durvalumab to chemotherapy, supported by NIAGARA, which improved event-free and overall survival and increased pathologic complete response rates across PD-L1 subgroups. For high-risk patients after surgery who did not receive neoadjuvant immunotherapy, adjuvant nivolumab is shown, based on CheckMate 274. Bladder preservation with trimodality therapy (maximal TURBT plus chemoradiation) suits selected patients. For cisplatin-ineligible patients, definitive treatment is cystectomy or chemoradiation, chosen according to fitness. The chart is a simplified board-review scaffold, and neoadjuvant cisplatin-based chemotherapy before cystectomy remains the reference standard for fit patients.

Trials behind this algorithm

VESPER trial, Perioperative dd-MVAC vs GemCis in MIBC Pfister C, et al., JCO, 2022, 32868138
NIAGARA Powles T et al, NEJM, 2024; PMID: 39282910
Checkmate 274, adj nivo Bajorin DF et al, NEJM, 2021, PMID: 34077643
BC2001 trial, RT w/wo chemo James ND et al, NEJM, 2012, PMID: 22512481

Background reading: Bladder Cancer board review notes.

Muscle-Invasive Bladder Cancer (MIBC): the algorithm in words

Curative-intent therapy by cisplatin-eligibility; adjuvant and bladder-preservation options. Starting point: Muscle-invasive bladder cancer cT2–4a N0 M0. Full background: Bladder Cancer notes.

Cisplatin-eligible (first-line): Neoadjuvant: ddMVAC or GC → cystectomy (cisplatin-based · VESPER); Perioperative: Durvalumab + chemo (NIAGARA).
Adjuvant (high-risk, no neoadj IO) (first-line): Adjuvant: Nivolumab (CheckMate 274).
Bladder preservation (first-line): Trimodality: Max TURBT + chemoRT (selected patients · BC2001).
Cisplatin-ineligible (first-line): Definitive: Cystectomy or chemoRT (per fitness).

Simplified board-prep scaffold; verify against current guidelines and primary literature. Neoadjuvant cisplatin-based chemo before cystectomy is standard for fit patients; perioperative durvalumab (NIAGARA) is a newer option; trimodality preservation suits selected patients.